Clinical Trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Dimensions: NCT03104413

Investigators

Affiliations

Organisations

  1. (1) AbbVie (United States), grid.431072.3

Sponsors/collaborators

Abstract

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active CD.

Methods

Condition: Crohn's Disease

Intervention: placebo for risankizumab administered as intravenous (IV) infusion.

Recruitment information

Gender: All

Trial period

2017-2021

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry